Cardiff Oncology has been granted a patent for a method to treat lung or gastric cancer by administering FGFR and PLK1 inhibitors. The method aims to inhibit cancer progression. GlobalData’s report on Cardiff Oncology gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Cardiff Oncology Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Cardiff Oncology, Personalized medicine biomarkers was a key innovation area identified from patents. Cardiff Oncology's grant share as of April 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.

Combination treatment for lung or gastric cancer

Source: United States Patent and Trademark Office (USPTO). Credit: Cardiff Oncology Inc

A recently granted patent (Publication Number: US11957677B2) discloses a method for therapeutically treating lung cancer or gastric cancer by administering a combination of a fibroblast growth factor receptor (FGFR) inhibitor and onvansertib to inhibit the progression of the cancer. The method involves identifying subjects with FGFR-amplified cancer or cancer with FGFR overexpression and administering the combination treatment to them. The patent also covers scenarios where the subject has previously received FGFR inhibitor treatment but did not respond well, or is known to be resistant to FGFR inhibitor therapy.

Furthermore, the patent includes methods for sensitizing lung cancer or gastric cancer cells to an FGFR inhibitor by contacting the cancer cells with a composition containing onvansertib. This sensitization process can occur in vitro, ex vivo, or in vivo, and involves determining the effectiveness of the sensitization after contact with the composition. The patent also covers the administration of the FGFR inhibitor to the cancer cells after sensitization, highlighting a comprehensive approach to treating these types of cancer using a combination of onvansertib and FGFR inhibitors.

To know more about GlobalData’s detailed insights on Cardiff Oncology, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies